RADYONÜKLİD TEDAVİLERDE DOZ HIZI ÖLÇÜMLERİ VE HASTA TABURCU EDİLME ZAMANININ DEĞERLENDİRİLMESİ
Amaç: Yatarak radyonüklid tedavi gören kanser hastalarından yayılan radyasyonun doz hızlarını ölçmek, ölçümsonuçlarına göre hastaların taburcu edilebilme koşullarını belirlemektir.Gereç ve Yöntem: Çalışmamıza 3700, 5550 ve 7400 Megabecquerel (MBq) aktivite miktarlarında İyot 131 (131I)tedavisi uygulanan 576 tiroit kanseri hastası, 3700, 5550 ve 7400 MBq aktivite miktarlarında Lutesyum-177 (177Lu)-DOTA-(Tyr3)-octreotate (DOTATATE) uygulanan nöroendokrin tümörlü hasta, 7400 MBq aktivite miktarında 177Lu-Prostat Spesifik Membran Antijen (PSMA) uygulanan prostat kanseri olmak üzere toplam 245 hasta, 1500-4500 MBqaktivite miktarı aralığında Yitrium-90 (90Y) tedavisi uygulanan 19 hasta olmak üzere toplamda radyonüklid tedaviuygulanan toplam 840 hasta alındı. Doz hızları Geiger-Müller (GM) problu detektörle 1 m mesafeden ölçüldü. Doz hızıölçümleri >30 μSv/sa olan hastaların tedavi ünitesinde yatırılmasına devam edildi ve 48. saatte doz hızı ölçümleri tekraryapıldı.Bulgular: 24. saatte ölçülen doz hızı ortalamaları 131I tedavilerinde 3700, 5550 ve 7400 MBq için sırasıyla; 24.7±7μSv/sa, 52.1±17 μSv/sa ve 66.7±15 μSv/sa; 177Lu- DOTATATE tedavilerinde 3700, 5550 ve 7400 MBq için sırasıyla;3.7±1, 5.1±2 ve 7.1±3 μSv/sa, 177Lu-PSMA tedavisinde 7400 MBq için 7.2±3 μSv/sa ve 90Y mikroküre tedavisinde4±0.3 μSv/sa olarak bulundu. 3700, 5550 ve 7400 MBq 131I tedavilerinde 48. saatteki doz hızı ise 13±6, 13.2±5 ve17.2±4 μSv/sa olarak bulundu.Sonuç: Bu sonuçlara göre 3700 MBq 131I, tedavilerinde hastaların en az 24 saat, 177Lu ve 90Y tedavilerinde hastaların enfazla 24 saat nükleer tıp servisinde kurşun izolasyonlu odalarda yatırılmaları, 5500 ve 7400 MBq 131I tedavisi uygulananve Türkiye Atom Enerjisi Kurumu (TAEK) tarafından belirlenen kritere göre doz hızı >30 μSv/sa olarak ölçülenhastaların 48 saat yatırılmalarının yeterli olduğu belirlendi.
THE EVALUATION OF DOSE RATE MEASUREMENTS AND DISCHARGE TIME AFTER RADIONUCLIDE THERAPY
Objective: The aim of this study is to measure radiation dose rate from hospitalized patients and to determine release dose for discharge time after radionuclide therapy. Materials and Methods: Our study included 840 patients undergoing radionuclide therapy in which 576 patients were treated by different doses of iodine: 3700, 5550 ve 7400 MBq, 144 patients weere treated with variable amounts of 177Lu-DOTATATE : 3700 and 7400 MBq, 245 patients were subjected to 177Lu-PSMA therapy with activity range 1500-4500 MBq and 19 patients were arbitraryly selected for 90Y microsphere therapy. Dose rates were measured at a distance of 1 meter from patients via Geiger- Müller (GM) probe. Dose rate readings >30 μS/h were repeated at 48 hours. Results: The average dose rate measured at 24 hours after administration of 3700, 5550 and 7400 MBq 131I was 24.6±7 μSv/h, 52.3±17 μSv/h and 66.7±15 μSv/h respectively, the average dose rate was 3.7±1, 5.1±2 and 7.1±3 μSv/h after administration of 3700, 5550 and 7400 MBq 177Lu-DOTATATE respectively; whereas the dose rate was 4±0.3 μSv/h in 90Y microsphere treatment and 7.2±3 μSv/h after administration of 7400 MBq 177Lu-PSMA. The mean dose rate after 48 hours following radioiodine therapy using activity of 3700, 5550 ve 7400 MBq 131I was 13±6, 13.2±5 ve 17.2±4 μSv/h repectively. Conclusion: We concluded that patients treated with 3700 MBq 131I must stay in lead-shielded rooms at least 24 hours and patients treated with 5550 and 7400 MBq 131I should stay up to 48 hours to assure dose rate less than 30 μSv/h as recommended by TAEK, while in 177Lu and 90Y treatment maximum 24 hours is found adequate for discharge of patients.
___
- Demir M, Abuqbeitah M, Uslu-Besli L, Yıldırım Ö,
Yeyin N, Çavdar İ at al. Evaluation of radiation
safety in (177)Lu-PSMA therapy and development
of outpatient treatment protocol. J Radiol Prot
2016;36(2):269-78
- Demir M, Parlak Y, Çavdar İ, Yeyin N, Tanyıldızı
H, Gümüser G at al. The evaluation of urine activity
and external dose rate from patients receiving radioiodine therapy for thyroid cancer. Radiat Prot
Dosimetry 2013;3:1–5.
- Calais PJ, Turner JH. Radiation safety of outpatient
177Lu-octreotate radiopeptide therapy of
neuroendocrine tumors. Ann Nucl Med. 2014
Jul;28(6):531-9.
- Culver CM, Dworkin HJ. Radiation Safety
Considerations for Post-Iodine 131 Thyroid Cancer
Therapy. J Nucl Med 1992; 33:1402-05.
- Ravichandran R, Binukumar JP, and Saadi AA.
Estimation of effective half life of clearance of
radioactive Iodine (131I) in patients treated for
hyperthyroid is mand carcinoma thyroid. Indian J
Nucl Med 2010; 25:49-52.
- Yeyin N, Demir M. Hasta ve atıklarından çevreye
salınan radyasyon miktarının belirlenmesi ve doz
hızı ölçümleri. 1.Ulusal Sağlık Kuruluşları Çevre
Yönetim Sempozyumu Yayınları, İstanbul, 29-30
Kasım 2012.
- European Commission Radiation Protection 97:
Radiation Protection Following Iodine-131 Therapy
(Exposure Due to Out-Patients or Discharged
Inpatients). Luxembourg, Belgium: Office for
Official Publications of the European Communities;
1998.
- Vetter RJ. Regulations for radioiodine therapy in the
United States: current status and the process of
change. Thyroid 1997; 7:209–11.
- Gulec SA, Mesoloras G and Stabin M, Dosimetric
Techniques in 90Y-Microsphere Therapy of Liver
Cancer: The MIRD Equations for Dose Calculations,
J Nucl Med. 2006;47(7):1209-11.
- Valkema R, Pauwels SA, Kvols LK, Kwekkeboom
DJ, Jamar F, de Jong M at al. Long-term follow-up
of renal function after peptide receptor radiation
therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and
(177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med.
2005; 46:83–91.
- Murthy R, Nunez R, Szklaruk J, Erwin W, Madoff
DC, Gupta S. et al. Yttrium-90 Microsphere Therapy
for Hepatic Malignancy: Devices, Indications,
Technical Considerations, and Potential
Complications. Radiographics 2005; 25: 41-55.
- Paganelli G, Bodei L, Handkiewicz Junak D, P.
Rocca, S. Papi, M. Lopera Sierra at al. 90Y-DOTA -
D-Phe(1)-Try(3)-octreotide in therapy of
neuroendocrine malignancies. Biopolymers 2002;
66:393–8.
- National Council on Radiation Protection and
Measurements. Mis administration of radioactive
material in medicine: scientific background.
Bethesda, MD: NCRP, 1991; 27.
- Ahmed Asm S , D emir M , Y aşar D , U slu İ .
Quantification of absorbed doses to urine bladder
depending on drinking water during radioiodine
therapy to thyroid cancer patients: a clinical study
using MIRDOSE3. Nucl Med Commun 2003;
24:749-59.
- TAEK (Türkiye Atom Enerjisi Kurumu), Radyasyon
Güvenliği Yönetmeliği Ek-5, 2004.
- Europan Comission. Radiation Protection Following
İodine-131therapy (Exposure Due To Out-Patients
Or Discharged İn-Patient). Directorate-General
Environment, Nuclear Safety and Civil Protection.
Radiation Protection 97, Elseviere Science Inc.
1998.3.
- Demir M. Nükleer Tıp Fiziği ve Klinik
Uygulamaları, İstanbul, 2014;368-72.
- Mazzaferri EL, Jhiang SM. Long-term impact of
initial surgical and medical therapy on papillary and
follicular thyroid cancer. Amer J Med 1994; 97:
418-28.